Castle Biosciences Q3 revenue $83M, raises FY2025 guidance to $327-335M; launches AdvanceAD-Tx test

CASTLE BIOSCIENCES INC

2025-Q3 EPS reported -$0.76 revenue$257,219,000

Revenue $83.0M (Q3 2025) vs $85.8M YoY; net loss $0.5M vs net income $2.3M.
Total test reports 26,841; DecisionDx-Melanoma and TissueCypher each exceeded 10,000 tests in a quarter for first time.
Full-year 2025 revenue guidance raised to $327-335M from $310-320M.
Launched AdvanceAD-Tx, a GEP test to guide systemic treatment for moderate-to-severe atopic dermatitis.
Non-dermatologic revenue up 67% YoY; adjusted EBITDA $9.2M vs $21.6M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.